Phase III trial of adjuvant 5-fluorouracil and adriamycin versus 5-fluorouracil, adriamycin, and polyadenylic-polyuridylic acid (poly A:U) for locally advanced gastric cancer after curative surgery: Final results of 15-year follow-up

Annals of Oncology

Volumn 19, Issue 3, 2008, Pages 520-526

  Jeung, H C ^a,b   Moon, Y W ^a,b   Rha, S Y ^a,b   Yoo, N C ^a,b   Roh, J K ^a,b   Noh, S H ^a,b   Min, J S ^a,b   Kim, B S ^a,b   Chung, H C ^a,b  

^a Yonsei University College of Medicine   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

Author keywords

Adjuvant chemotherapy; Chemoimmunotherapy; Gastric cancer; Poly A:U

Indexed keywords

DOXORUBICIN; FLUOROURACIL; POLYADENYLIC POLYURIDYLIC ACID;

ADJUVANT THERAPY; ADULT; ADVANCED CANCER; AGE DISTRIBUTION; AGED; ALOPECIA; ANEMIA; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG FATALITY; DRUG FEVER; DRUG TOLERANCE; FEMALE; FOLLOW UP; GASTRECTOMY; HUMAN; HUMAN TISSUE; INFECTION; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEX RATIO; SIDE EFFECT; SKIN PIGMENTATION; STOMACH CANCER; SURVIVAL RATE; SURVIVAL TIME; TUMOR BIOPSY; TUMOR DIFFERENTIATION; TUMOR LOCALIZATION;

ADENOCARCINOMA; ADJUVANTS, IMMUNOLOGIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; DOXORUBICIN; FLUOROURACIL; FOLLOW-UP STUDIES; IMMUNOTHERAPY; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, SECOND PRIMARY; POLY A-U; PROGNOSIS; STOMACH NEOPLASMS; SURVIVAL RATE;

EID: 40149085707     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdm536     Document Type: Article

References (30)

1. Hoel DG, Davis DL, Miller AB et al. Trends in cancer mortality in 15 industrialized countries, 1969-1986. J Natl Cancer Inst 1992; 84: 313-320.
2. Shin HR, Jung KW, Won YJ et al, 2002 Annual report of the Korea Central Cancer Registry: Based on registered data from 139 hospitals. Cancer Res Treat 2004; 36: 103-114.
3. Janunger KG, Hafström L, Glimelius B. Chemotherapy in gastric cancer: A review and updated meta-analysis. Eur J Surg 2002; 168: 597-608.
4. Hejna M, Wöhrer S, Schmidinger M et al. Postoperative chemotherapy for gastric cancer, Oncologist 2006; 11: 136-145.
5. Moertel CG, O'Connel M, Lavin PT. Chemotherapy of gastric cancer. Proc Am Assoc Cancer Res 1979; 20: 288 (Abstr 1979).
6. Ducret JP, Caillé P, Sancho Garnier H et al. A phase I clinical tolerance study of polyadenylic-polyuridylic acid in cancer patients. J Biol Response Mod 1985; 4: 129-133.
7. Nakano M, Braun W. Fluctuation tests with antibody forming spleen cell populations. Science 1966; 151: 338-340.
8. Johnson AG. Modulation of Immune System by Synthetic Polynucleotides. Springer Seminars, in Immunopathology, Vol. 2. New York, NY: Spring-Verlag 1979; 149-168.
9. Laccur J, Lacour F, Spira A. Adjuvant treatment with polyadenylic-polyuridylic acid in operable breast cancer; updated result of a randomized trial. Br J Med 1984; 288: 589-592.
10. Youn JK, Lacour F, Hue G. Inhibition of C3H/He mouse mammary tumor growth by combined treatment A cyclophosphamide and polyadenylic-polyuridylic acid, Cancer Res 1982; 42: 4706-4711.
11. Kajitani T. The general rules for the gastric cancer study in surgery and pathology, Jpn J Surg 1981; 11: 127-139.
12. Oota K, Sobin LH. Histological Typing of Gastric and Esophageal Tumors. Geneva, Switzerland: World Health Organization 1977.
13. Beahrs OH, Myers MM. Mannual for Staging of Cancer, 2nd edition. Philadelphia, PA: JB Lippincott 1983; 67.
14. Miller AB, Hoogstraten B, Staquet M et al. Reporting results of cancer treatment. Cancer 1981; 47: 207-214.
15. Greene FL, Balch CM, Page DL et al. AJCC Cancer Staging Manual, 6th edition. New York, NY: Springer-Verlag 2002; 99-103.
16. Kim JP, Lee JH, Kim SJ et al. Clinicopathologic characteristics and prognostic factors in 10 783 patients with gastric cancer, Gastric Cancer 1998; 1: 125-133.
17. Hayashi H, Ochiai T, Suzuki T et al. Superiority of a new UICC-TNM staging system for gastric carcinoma, Surgery 2000; 127: 129-135.
18. Hovanessian AG, Youn JK, Buffet-Janvresse C et al. Enhancement of natural killer cell activity and 2-5A synthetase in operable breast cancer patients treated with polyadenytic polyuridylic acid. Cancer 1985; 55: 357-362.
19. Youn JK, Kim BS, Youn JK et al. Adjuvant treatment of operable stomach cancer with polyadenylic-polyuridylic acid in addition to chemotherapeutic agents. Differential effect on natural killer cell and antibody-dependent cellular cytotoxicity. Int J Immunopharmacol 1987; 9: 313-324.
20. Miura D, Yoneyama K, Furuhata Y et al, Paclitaxel enhances antibody-dependent 'cell-mediated cytotoxicity of trastuzumab by a rapid recruitment of natural killer cells in Her-2 overexpression breast cancer. J Clin Oncol 2007; 25: 18s (Abstr 3503).
21. Gastrointestinal Tumor Study Group. Controlled trial of adjuvant chemotherapy follow-up curative resection for gastric cancer. Cancer 1982; 49: 1116-1122.
22. Coombes RC, Schein PS, Chilvers CED et al. A randomized trial comparing adjuvant fluorouracil, doxorubicin, and mitomycin with no treatment in operable gastric cancer. J Clin Oncol 1990; 8: 1362-1369.
23. Higgins GA, Amadeo JH, Smith DE et al. Efficacy of prolonged intermittent therapy with combined 5-FU and methyl-CCNU following resection for gastric carcinoma. Cancer 1983; 52: 1105-1112.
24. Imanaga H, Nakazato H. Results of surgery for gastric cancer and effect of adjuvant mitomycin C on cancer recurrence. World J Surg 1977; 2: 213-221.
25. Nakajima T, Takahashi T, Takagi K et al. Comparison of 5-fluorouracil with ftorafur in adjuvant chemotherapies with combined inductive and maintenance therapies for gastric cancer. J Clin Oncol 1984; 2: 1366-1371.
26. Sasako M, Yamaguchi T, Kinoshita T et al. Randomized phase III trial comparing S-1 monotherapy versus surgery alone for stage II/III gastric cancer patients (pts) after curative D2 gastrectomy (ACTS-GC study). Presented at the American. Society for Clinical Oncology Gastrointestinal Cancers Symposium, Orlando, FL: 2007 (Abstr 8).
27. Narahara H, Koizumi W, Hara T et al. Randomized phase III study of S-1 alone versus S-1 + cisplatin in the treatment for advanced gastric cancer (the SPIRITS trial). J Clin Oncol 2007; 25: 18s (Abstr 4514).
28. Cirera L, Balil A, Cirera L et al. Randomized clinical trial of adjuvant mitomycin plus tegafur in patients with resected stage III gastric cancer. J Clin Oncol 1999; 17: 3810-3815.
29. Popiela T, Kulig J, Czupryna A et al. Efficiency of adjuvant immunochemotherapy following curative resection in patients with locally advanced gastric cancer. Gastric Cancer 2004; 7: 240-245.
30. Niimoto M, Hattori T, Ito I et al. Levamisole in postoperative adjuvant immunochemotherapy for gastric cancer, A randomized controlled study of the MMC + Tegafur regimen with or without levamisole. Report I. Cancer Immunol Immunother 1984; 18: 13-18.